Faes Farma, S.a. · BME:FAE
Faes Farma — Investor Day (March 2024)
33 slides from Faes Farma's investor day presentation, March 2024
Slide 1: Capital Markets Day Faes Farma
Capital Markets Day Faes Farma March 2024
Slide 2: Index
Index 1// 2// 3// Faes Farma R&D&I as a Our commercial today strategic strategy priority 4// 5// 6// Industrial 2023 Results Close and projects and 2024 Q&A commitments
Slide 3: Faes Farma today
VW Faes Farma today dF FAES FARMA
Slide 4: Faes Farma at a glance
Faes Farma today Faes Farma at a glance Direct presence Iberia + subsidiaries Presence of Faes products via partners and exports Diversification Profitability Geographical footprint Industrial footprint Employment ~420M€ ~53M€ ~122M€ Presence in 8 ~1800 Pharma income AH&N income EBITDA >130 countrie
Slide 5: Continuing to advance our ESG framework and governance
Faes Farma today Continuing to advance our ESG framework and governance Key figures and milestones ESG 2023 36% of women in management positions Boosting the Cybersecurity capabilities, 54% of women on Sustainability and staff Compliance Obtaining the certificate LEED1 Gold in the new 55% of board m
Slide 6: R&D&I as a strategic priority
2// R&D&I as a strategic priority 6
Slide 7: Prioritising the generation of future value through R&D&I
R&D&I as a strategic priority– KPIs Prioritising the generation of future value through R&D&I Commitment to future ~110M€ ~25M€ ~100 FTEs value generation Invested in R&D&I in the last 5 years Invested in R&D&I Dedicated to R&D&I (2018 – 2023)1 in 20231 Strong pipeline of 4 6 21 12 Therapeutic Activ
Slide 8: R&D&I focuses on 4 therapeutic areas with high growth potential
R&D&I as a strategic priority– Therapeutic Areas R&D&I focuses on 4 therapeutic areas with high growth potential strategic Allergies Gastrointestinal Bone Pain Therapeutic Inmunomodulation areas Target Indication - Allergic rhinitis - Ulcerative colitis - Vitamin D deficiency - Painful muscle spasms
Slide 9: We aim to build a research pipeline for a new IND/CTA project every 2/3 years
R&D&I as a strategic priority– Research pipeline We aim to build a research pipeline that will enable the entry of a new project in regulatory phase IND / CTA every 2 / 3 years Therapeutic area Project Research pipeline stage New key milestone - in progress 1 Early discovery 2 Screening 3 Optimisati
Slide 10: Innovation pipeline: milestones achieved in 2023, new launches planned 2025-2026
R&D&I as a strategic priority– Innovation pipeline Innovation pipeline: we have achieved our innovation milestones in 2023 and have new launches planned for 2025-2026 Therapeutic area Project Innovation pipeline stage New key milestone - in progress Clinical phases Early discovery Register Most rele
Slide 11: Our commercial strategy
3// Our comercial strategy 11
Slide 12: Consolidated product portfolio with further growth potential
Our commercial strategy– Product portfolio Consolidated product portfolio with further growth potential Strategic products Bilastine Calcifediol Mesalazine Other products Increased efficacy in the Treatment for ulcerative Other proprietary and Leading global Antihistamine licensed products that trea
Slide 13: We continue to consolidate our direct sales areas
Our commercial strategy– Direct sales areas We continue to consolidate our direct sales areas Direct presence Presence via partners A. Pharma Iberia Iberia Medium-term target markets Direct commercialization Total sales direct commercialization …a consolidated, resilient and flexible business, able
Slide 14: Iberia, a consolidated, resilient and flexible business
Our commercial strategy– Direct sales area – A. Farma Iberia Iberia, a consolidated, resilient and flexible business, capable of overcoming the challenges that have marked recent years A consolidated business and …diversified into three …and with a proven track of high contribution to the Iberia str
Slide 15: In LATAM, we improved our position in all our markets
Our commertial strategy– Direct sales area – B. Faes LATAM In LATAM, we improved our positionin in all our markets, with a growth path to the top 25 position Our Iberia subsidiaries CAC1 Colombia Chile Mexico Ecuador Peru Direct commercialization LATAM x1,2 x1,2 x1,7 Total income [M€, ‘20 vs.’23] x3
Slide 16: We continue to consolidate our commercial platform in MEA
Our commertial strategy– Direct sales area– C. Faes OMA We continue to consolidate our comercial platform in MEA, with prospects for growth, especially in the Middle East Presence in more than 40 Iberia countries Direct commercialization Significant ~26M€ >50 ~7M Position #28 LATAM commercial income
Slide 17: Maximising value of strategic products through global alliances
Our commercial strategy– Licensing-out business Maximising the value of our strategic products through a network global alliances with top-tier partners Revenue performance of the licensing-out business [M€; 2014 - 2023] Iberia Direct commercialization x5,4 +21% CAGR 95M€ 100M€ 100M€ LATAM 90M€ Othe
Slide 18: Bilastine, our leading antihistamine
Our commercial strategy– Licensing-out business- Bilastine Bilastine, our leading antihistamine, which will continue to maintain its high value in the coming years Top antihistamine Markets Faes Farma and presence of bilastine1 [R6A, 2023, M€, licensed-out market] Most relevant milestones Iberia Mar
Slide 19: Calcifediol, will continue to grow in current markets and new launches
Our commercial strategy– Licensing-out business- Calcifediol Calcifediol, will continue to grow in current markets and through new launches Top Faes Farma Vitamin D Markets and presence of Calcifediol Faes1 [2023, M€, licenses-out market] Most relevant milestones Approval of our manufacturer and pen
Slide 20: Mesalazine: further growth via new product launches
Our commercial strategy– Licensing-out business- Mesalazine Mesalazine: further growth via new product launches as we develop the most complete range for this molecule Top Faes Farma Mesalazine Markets and presence of Faes1 [2023, M€, licenses-out market] Most relevant milestones Iberia UK 120 M€ Un
Slide 21: Industrial projects
Industrial projects dF FAES FARMA
Slide 22: Excellence and specialisation of our industrial footprint
Industrial projects – Our industrial footprint Excellence and specialisation of our industrial footprint Faes Farma’s industrial footprint [ new industrial expansion] Specialisation by product and Cost efficiency and Consolidated know how in Automation of regional production scale high-value technol
Slide 23: The new Derio plant will come into operation at the end of this year
Industrial projects- Derio The new Derio plant will come into operation at the end of this year Derio plant: Timetable and key milestones [high-level vision] 2021 2022 2023 2024 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 After the process of Desing and engineer
Slide 24: The new Derio plant will double our industrial capacity
Industrial projects- Derio …and will allow us to double our industrial capacity, to incorporate new technologies of added value and to strengthen our focus on operational excellence The new pharmaceutical plant will allow us to… ...double our industrial …to incorporate new high- …to strengthen our f
Slide 25: AH&N: the new ISF plant will consolidate our leading position
Industrial projects- ISF AH&N: the new ISF plant will play a key role in consolidating our leading position in the market for early age animal specialty nutrition New ISF plant – Special foods for the early ages ISF construction process status Vertical diversification Strengthening our Strengthe
Slide 26: 2023 Results and 2024 commitments
5// 2023 Results and 2024 commitments 26
Slide 27: 2023 marks twelve years of profitable growth for our business
2023 Results 2023 marks twelve years of profitable growth for our business Total income PBT [M€; 2011 - 2023] [M€; 2011 - 2023] Despite the great x2,4 x8,3 challenges faced in 2022 - +8% CAGR 473 +19% CAGR 103 2023… 429 94 - End of bilastine exclusivity 390 in Spain and Europe 74 - Devaluation of th
Slide 28: Growth driven by strategic products and international business
2023 Results …driven mainly by our key growth drivers: the strategic products and international business Total income: Product evolution Total income: Business area evolution [M€; 2022 vs. 2023] [M€; 2022 vs. 2023] 3M€ 5M€ (7M€) (7M€) 473M€ 4M€ 473M€ 13M€ 11M€ 462M€ 462M€ Income Strategic Other AH&N
Slide 29: 2024 guidance: continued growth driven by international expansion
2024 Commitments In 2024, even with some major challenges on the horizon, we will continue to grow especially driven by our international business expansion Guidance 2024 Impacts + 2024 Impacts - 2024 Other issues with an impact on the P&L • Double-digit growth in • Increase in personnel 2024 LATAM
Slide 30: We continue to invest in growth and prioritise shareholder returns
Resource allocation We continue to invest in the growth of our business and to prioritise shareholder returns Capital Allocation Priorities aligned with our strategy Strengthening our Growing the business by A stronger 1 Organic investment in our commitment to industrial strengthening the business…
Slide 31: Close and Q&A
6// Close and Q&A 31
Slide 32: Faes Farma: Caring for tomorrow, today
Ih FAES FARMA Caring for tomorrow, today
Slide 33: Disclaimer
DISCLAIMER This presentation has been prepared and published by Faes Farma Group and is presented for informational purposes only. This presentation is not a brochure, nor is it an offer or recommendation to make an investment. This presentation does not imply any subscription commitment, nor an off